Edge Therapeutics (EDGE) Sees Strong Trading Volume

Edge Therapeutics Inc (NASDAQ:EDGE) saw strong trading volume on Friday . 6,794,166 shares were traded during mid-day trading, an increase of 751% from the previous session’s volume of 798,418 shares.The stock last traded at $0.68 and had previously closed at $0.57.

Separately, ValuEngine raised Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Edge Therapeutics currently has an average rating of “Hold” and an average price target of $17.00.

Edge Therapeutics (NASDAQ:EDGE) last posted its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.16.

A number of large investors have recently bought and sold shares of EDGE. Millennium Management LLC increased its holdings in Edge Therapeutics by 2,686.1% in the second quarter. Millennium Management LLC now owns 510,212 shares of the biotechnology company’s stock valued at $526,000 after buying an additional 491,899 shares during the last quarter. BlackRock Inc. increased its holdings in Edge Therapeutics by 24.5% in the first quarter. BlackRock Inc. now owns 1,177,470 shares of the biotechnology company’s stock valued at $1,389,000 after buying an additional 231,628 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Edge Therapeutics in the second quarter valued at $163,000. 34.22% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2018/11/30/edge-therapeutics-edge-sees-strong-trading-volume.html.

Edge Therapeutics Company Profile (NASDAQ:EDGE)

Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.

See Also: Understanding Average Daily Trade Volume

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit